Guidant is turning from randomized trials to national patient registries to identify underserved heart failure patient groups that can benefit from implantable cardioverter defibrillators
Join thousands of industry professionals who rely on Medtech Insight for daily insights
Already a subscriber?
There is still no clarity on how life sciences will be treated in the final agreement.
NICE’s three-pronged lifecycle approach to healthtech evaluations includes late-stage assessments (LSA), which will be the focus of a short consultation in August.
Roche has taken steps to mitigate potential tariff exposure that include shifting inventories and increasing US production of medicines. The company also initiated a tech transfer for one of its most exposed products to a US manufacturing site.
